**Date:** June 16, 2022

To: Dean Robert N. Golden, MD, UW-SMPH - Dr. Richard Moss, Designated

Representative

Karen Timberlake, Secretary-designee, DHS - Dr. Jon Meiman, Designated

Representative

Preston Cole, Secretary, DNR - Greg Pils, Designated Representative

Randy Romanski, Secretary, DATCP - Gilbert (Gil) Kelley, Designated Representative

Greg Pils, Chair

Dr. Robert Corliss, Vice Chair
Jessica Blahnik, Member
Gina Green-Harris, Member
Gilbert (Gil) Kelley, Member
Jeffrey Kindrai, Member
Dr. Jon Meiman, Member
Dr. Richard Moss, Member
Dr. Christopher Strang, Member
Steve Geis, DNR Alternate
Zana Sijan, DNR Alternate
Paula Tran, DHS Alternate
Anna Benton, DHS Alternate

FROM: Dr. James Schauer, Secretary

Director, Wisconsin State Laboratory of Hygiene

RE: Wisconsin State Laboratory of Hygiene Board of Directors Meeting

Wisconsin State Laboratory of Hygiene

In-Person/Online Meeting

June 21, 2022, 1:00 p.m. - 4:00 p.m.

CC: Kevin Karbowski

Jan Klawitter Nancy McLean Dr. Errin Rider David Webb Dr. Al Bateman

# WISCONSIN STATE LABORATORY OF HYGIENE BOARD OF DIRECTORS

# **MEETING NOTICE**

Tuesday, June 21, 2022 1:00 p.m. – 4:00 p.m.

# MEETING LOCATION 2601 Agriculture Drive, Madison, WI 53718

**Notice is hereby given** that the Wisconsin State Laboratory of Hygiene Board of Directors will convene at 1:00 p.m. on Tuesday, June 21, 2022 in-person and via teleconference.

**Notice is further given** that matters concerning Wisconsin State Laboratory of Hygiene issues, program responsibilities or operations specified in the Wisconsin Statutes, which arise after publication of this notice may be added to the agenda and publicly noticed no less than two hours before the scheduled board meeting if the board Chair determines the matter is urgent.

**Notice is further given** that this meeting may be conducted partly or entirely by teleconference of videoconference.

**Notice is further given** that questions related to this notice, requests for special accommodations, or requests for a public appearance are addressed by the Wisconsin State Laboratory of Hygiene Administrative Offices by phone at (608) 890-0288 or in writing to the Wisconsin State Laboratory of Hygiene, 465 Henry mall, Madison, Wisconsin, 53706

ORDER OF BUSINESS: See agenda.

Respectfully submitted,

In Ja Soli

James J. Schauer, PhD, P.E., M.B.A.
Secretary, Wisconsin State Laboratory of Hygiene Board of Directors
Director, Wisconsin State Laboratory of Hygiene

# 2601 Agriculture Drive Madison, WI 53718

# AGENDA

PROCEDURAL	L ITEMS	<u>PAGE</u>
Item 1.	ROLL CALL	2
Item 2.	APPROVAL OF MINUTES	3
Item 3.	REORGANIZATION OF AGENDA	4
Item 4.	PUBLIC APPEARANCES	5
Item 5.	BOARD MEMBERS' MATTERS	7
<b>BUSINESS ITI</b>	<u>EMS</u>	
Item 6.	WISCONSIN'S OPIOID EPIDEMIC  Paul Krupski  Director of Opiate Initiatives, Wisconsin Department of Health Services	8
Item 7.	ROLE OF PHARMACIES IN FUTURE POINT OF CARE TESTING  Dr. Casey Gallimore  Associate Professor / Co-Director of the School's Interprofessional Education Program at the University of Wisconsin School of Pharmacy  &  Dr. Andrea Porter  University of Wisconsin-Madison Associate Professor (CHS) / Director of Pharmacotherapy Laboratories, University of Wisconsin-Madison School of Pharmacotherap	
Item 8.	FINANCIAL REPORT	10
Item 9.	APPROVAL OF FY23 BUDGET	18
Item 10.	CONTRACTS REPORT	19
Item 11.	DIRECTOR'S REPORT	20
	Strategic Plan Update - Kevin Karbowski	
	Water Boil Notice Report - Dave Webb	21
	Space Update - Dave Webb	
	PFAS Testing - Dave Webb	
	Monkeypox Testing - Dr. Alana Sterkel	
	Public Relations Report - Jan Klawitter	22

June 21, 2022

#### **PROCEDURAL ITEM**

Item 1. ROLL CALL

#### **Description of Item:**

Roll call of attendance at Board Meeting led by Board Chair

#### **Suggested Board Action:**

Submit roll call

### **Staff Recommendation and Comments:**

Roll call will be recorded by Board Secretary

#### **PROCEDURAL ITEMS**

Item 2. APPROVAL OF MINUTES

#### **Description of Item:**

The draft minutes of March 15, 2022 board meeting are submitted for approval

#### **Suggested Board Action:**

Motion: Approve the draft minutes of the March 15, 2022 board meeting as submitted

#### **Staff Recommendation and Comments:**

Approve draft minutes

Once approved, minutes become part of the public record and area posted on the WSLH website: <a href="http://www.slh.wisc.edu/about/board/board-meetings-agendas-and-minutes/">http://www.slh.wisc.edu/about/board/board-meetings-agendas-and-minutes/</a>

#### **APPROVED MINUTES**

### Wisconsin State Laboratory of Hygiene Board of Directors Meeting March 15, 2022 1:00pm-4:00pm

MEMBERS PRESENT: Chair James Morrison, Vice Chair Greg Pils, Secretary Dr. James

Schauer, Dr. Richard Moss, Gil Kelley, Jeffery Kindrai, Dr.

Robert Corliss, Dr. Jon Meiman

WSLH STAFF PRESENT: Dr. James Schauer, Dr. Errin Rider, Dave Webb, Cynda

DeMontigny, Jan Klawitter, Kevin Karbowski, David Gay, Jim

Sterk, Steve Strebel, Allen Benson

**DNR STAFF PRESENT:** Zana Sijan, Steve Geis

**GUESTS PRESENT:** Mr. Andy Johnson, Dr. Keith Poulsen

#### **PROCEDURAL ITEMS**

#### Item 1. ROLL CALL

Chairman Morrison called the meeting to order and Greg Pils seconded the motion.

Chairman Morrison initiated and conducted the roll call of the Board members. All Board Member seats or their designated representatives were present except for Jennifer Blahnik, Gina Green-Harris, and Dr. German Gonzalez. There was 1 attendee on the public line.

#### Item 2. <u>APPROVAL OF MINUTES</u>

- February 18, 2022
- December 21, 2021

#### Approve the minutes of the December 21, 2021 Board meeting as submitted.

Mr. Pils made the motion to approve, Dr. Moss seconded the motion. The voice vote to approve the minutes was unanimous.

Approve the minutes of the February 18, 2022 Board meeting with edit.

Jeff Kindrai asked for the following correction to his statement at the bottom of page 8 to more accurately reflect what he was saying at the Feb. 11, 2022 meeting:

Mr. Kindrai: Playing an assurance role is important, as the state lab keeps a foot in the game just in case, so there are no delays. He would encourage WSLH's involvement in PFAS testing outside UCMR5 such as blood work for SHOW and other environmental areas where there may not be as much capacity.

Chairman Morrison entertained a motion to approve the minutes with Mr. Kindrai's amended comment. Mr. Pils made the motion and Mr. Kindrai seconded the motion. The voice vote approving the minutes was unanimous.

#### Item 3. REORGANIZATION OF AGENDA

There was no request to reorganize the agenda

#### Item 4. <u>PUBLIC APPEARANCES</u>

None

#### Item 5. BOARD MEMBERS' MATTERS

Dr. Moss has to leave at 2pm, today.

Thanks to all in their participation in the February 28, 2022 Special meeting and for a good resolution – Dr. Moss commented that Mr. Pils' letter to legislators was particularly effective.

Mr. Kindrai brought up the increase in overdoses during pandemic and being attentive to the roles labs play in the public health factors, and additional attention may be needed – No action required, just request for attention – Mr. Kindrai interested in the topic, due to an increase in his county.

Dr. Schauer responded that WSLH is also paying attention; it is something we could present at the June board meeting and work with DHS to get onto the agenda.

#### **BUSINESS ITEMS**

#### Item 6. FACILITIES PLANNING

Dave Webb

Dynamic situation – First of many conversations on this topic; We are assessing our facility, footprint, overall space:

• Stovall Hall/Henry Mall – getting to be outdated with increasing maintenance costs

- Walton Commons OIS –Not cost-effective with some concerns over the private lease, as we have less control over the intricacies of lease.
- Ag Drive DOA Bldg, DOA staff in the building Immediate access to correct and appropriate tradespeople that can serve our needs Even with new wing, 6-7 years ago, we outgrew it as we moved into it. The building is limiting growth.

#### **New Space Options**

- Expansion space for a wing to the north of Ag Drive DOA/State land State land, pros and cons
   Space, timing and financing
- Consolidating Stovall and Walton Commons into a new/remodeled building and possibly including some Ag Drive programs, to alleviate space pressure.
- Remodel Stovall Analysis embarked on particular floor, but no overall overhaul It's to buy time
- Hill Farms Add additional space at Hill Farms, could renovate space there.

#### Potentials for funding

- Request made to WI American Rescue plan via DHS/DOA for possible funding
- Discussion in Congress APHL and other partners about state lab infrastructure model
- Public-Private arrangements. Build-to-lease, Pros/Cons to all arrangements
- Traditional WI State Appropriations

We are going forward with two ongoing architectural engineering (AE) studies at Hill Farms and Ag Drive to determine capacity/cost/timing.

Public/Private build-to-lease arrangement in terms of consolidation/function Stovall 65000 square feet in Stovall, but not particularly efficient

Looking at 60/80/100 million dollar figures to replace Stovall for HM and WC replacement. Big topic is fate of Stovall – We are working with Mark Wells and his colleagues to see what can be done.

As far as a PP investment, we are a decent risk for build-lease arrangements. UW-Madison Campus has used this model and Dr. Moss has experience and understanding, has been working on details and campus has used this model, and it's a good possible option going forward – Stovall is not a rational investment.

There are two options for clinical lab needs: Replacement and addition to our clinical activities

There are only two rational options to financing: 1) Congress providing significant money, and 2) buildto-lease.

Dr. Moss advised that they have been pursuing this model with the Biomedical Swine Research Lab. It's a very specialized building with biomedical innovation and pathogen-free space. They have been working with Johnson Controls, where after 20 years, ownership is transferred to lessee. It would be hard for financiers of the project to offload to another lessee. It's an efficient model, low initial cost and

doesn't require cash up front. Lease payments cover annual operating & maintenance cost, so no burden financially to the rest of university. Ohio State has built its entire medical research facility with this model. There are multiple likely partners in the Madison area and WSLH is a very good, low-risk investment.

University Research Park – Lease cost has to be competitive. What is attractive is that WSLH would be a good, long-term tenant and we could do away with lease-to-own and just hold a lease over decades. Build a building in 2-3 years as opposed to 20 years.

Mr. Kindrai – Henry Mall was going to be decommissioned – How much specialty do you need in the building? As delays in building occur and willingness to do it on leased basis are encouraged Jamie- Long term plan that HM will be knocked down and the replacement will not be ours. We should plan for no more than 7-10 years maximum, but it's likely not within the next three years. We would have BSL2 at the new lab (as opposed to the BSL3 at Ag Drive, which we have no intention to duplicate), which makes it an easier investment for this sort of program.

Dr. Schauer – We will pursue the AE studies, consider adding a wing on Ag Drive with federal funding – We can continue to pursue buildings and we will see where Congress comes down. Meanwhile, we should be looking at a more specific plan for going forward in the next year. WSLH's request to Board is to please let us know what else we should be doing.

Dr. Moss advises Ag Drive wing could also be a build-to-lease arrangement.

#### Item 7. NEWBORN SCREENING CARD COST

Dr. Errin Rider

In 2011, the authority to increase Newborn Screening Card fees moved from the WSLH board to under DHS; NBS Card fees were last increased in 2010.

NBS costs have consistently increased due to program enhancements and inflation. While we have continued to discuss with this with DHS Administration, the process has stalled and no progress is being made.

The WSLH receives 53.7% of the card fee for newborn screening laboratory operations and DHS receives 46.3% for newborn screening program operations.

Costs of laboratory operations have increased by 46%, due to second-tier testing, regulatory requirements and legislative addition of disorders – Courier costs increased by \$400,000 and new disorders continue to be added. Anticipated costs for next year show only 62% covered by the card, leaving the WSLH to cover 38% by other means, with a continued 3% anticipated annual increase in cost annually.

This situation is unsustainable and it's going to get worse every year. We are not necessarily asking for recommendations from board, but this is necessary information of which the members need to be aware.

Dr. Schauer advised WSLH is working with leadership to see if we can work with this, and politically, operationally, these numbers affect the bottom line and the ability to support the lab. The main message: This is one of the bigger threats to WSLH and difficult decisions may have to be made, like dropping follow-up testing for PKU that we've done for free. Maybe DHS can do the follow-up? We cannot simply cover the costs by increasing fees in other areas. Dr. Schauer made it clear that this was not directed at Board Member, Dr. Jon Meiman.

Dr. Meiman stated he had been briefed by Anna Benton, but doesn't have a whole lot to add; we are stuck. A lot of challenges. The program is desirable, but the funding isn't there. Will require more negotiation. Raising the fee for the card would require an administrative rule change.

Dr. Schauer advised that Newborn Screening cards are paid by insurance through hospitals which do not want to see the fee increased. It is important that the WSLH Board understands that this is presently one of the biggest challenges for us, going forward.

This will be addressed more in the coming year, as it is becoming urgent, and WSLH may need to talk about cutting costs and cutting services. WSLH will discuss further in September.

# Item 8. NATIONAL ATMOSPHERIC DEPOSITION PROGRAM (NADP) AERO-ALLERGEN NETWORK

Mr. Andy Johnson

Maine Department of Environmental Protection Bureau of Air Quality and Chair, NADP Aeroallergen Monitoring Science Committee

Dr. Schauer introduced speaker, Mr. Andy Johnson, along with WSLH's Dr. David Gay, program coordinator for the NADP program, which came to the WSLH 3 years ago, funded by federal, state and tribal entities. Acid deposition, mercury, environmental contaminants –

Mr. Johnson Subcommittee – Air Quality, active in air allergens – Set NADP data @ country.

Disparities, access...

Topic Aeroallergens is component

Public Health Issue:

Expanded monitoring important need:

Access to Aeroallergen data important, why?

#### NADP's role:

Allergic Rhinitis increased from 1970-2000, from 10-30% in US population. Outdoor aeroallergens (pollen/mold) exacerbate health conditions including asthma, allergic rhinitis, COPD and conjunctivitis. 25 million people have asthma and number is growing.

Cutaneous sensitivities have increased. Quality of life issues: large effects on morbidity, well-being, school attendance, work productivity, associated with increasing health care costs. (\$16B annually)

Climate Change: Plants are responding to warmer temps, leading to more pollen and increasing pollen allergenicity. Increase in CO increases spore abundance – Seasons start earlier and last longer – Wildfires, air pollution, aggravating factors piling on humans.

Expanded monitoring – Limited network of sites that can measure - Small number of individuals who fund and supply data for allergy clinics – No centralized network.

70-80 sites in the US, as opposed to 250 sites in NADP – National network would help us figure the quantity and geo-spatial coverage. Data important for being able to validate existing models. While we cannot measure everything, we use computer models to give estimate. We need more data to represent all the different kinds of models.

Utilizing satellite imagery, temperature, and an increase in Google searches to indicate things are happening for onsets of pollen seasons.

Improved Access to data – Not widely distributed or well-coordinated – Tribal sites may do some, but trying to ID where it is happening is no small challenge. Good access would allow people to see the pollen season beginning to start medication 6 weeks ahead of exposure. Timing would help treatment efficiency and efficacy.

There is a history in current sites of resistance to share data - perhaps due to financial concerns. Clinicians have been reluctant to engage or share their data; they have laid out their own resources – are willing to sell the data – scientists not always getting data or easy access, cannot always pay for it. Most of the public does not have access to this data, and this data would be helpful to public health organizations, climate change science, etc -. EPA has identified this as a leading climate change factor.

How to address issues. CSTE & CDE – Pollen Summit 2015-2019 – Stake holders brought in – Already identified the reasons, but no solutions – Began to ask how to create a network and set about establishing a Network.

#### Mission statement of NADP -

Air quality issues affecting ecosystems and human health. Addition of other chemical/biological species – Suited for considering monitoring effort.

- Worldwide networks, NADP held up as model with a good reputation
- NADP has centralized operations, QA/QC, publicly accessible database
- Public database
- Policy and procedures already in place
- Organization of NADP allows partners to pay to participate in the network so the financial structure is already in place.

Standardized procedures - Siting criteria, sampling frequency, level of speciation required, approved

AMSC – Proposed in 2016 and provisionally approved for one year – After first year, a lot of success and good engagement – 2017-2021, renewed for another 4 years beyond that, recently. Conducted methods comparison study.

Study compared methods – Proposed 2021 pollen study, March – October (Madison into November) Duke forest, NC/Madison, WI/ Logan, UT –Looking at historical methods for pollen/allergen collection and current NADP processes, and using filters that would otherwise just be thrown away.

In midst of doing data assessment, compiling data from all sites, massage data for analysis – Site in Madison, of 3 major categories – Best correlation

Trees – Publish paper on it

Pollensense is a \$3750 particulate sensor – Air comes in, traps particulates on a tape, camera with microscope looks at it, takes a photo over minutes which can be sent and evaluated – The actual sample doesn't go away, meaning data can be reanalyzed. Being identified as particulate, not just pollen – Can identify variety of things and constant, real-time use. Methods comparison study vs traditional methods. It is an affordable price, and as art, it learns over time.

It fits within our mission and is timely. Dr. Schauer advised that we may be in a unique position to be a partner in this area. Chairman Morrison thanked Mr. Johnson and acknowledged the industrial hygiene assessment struggle with crossover in this area. Primarily limited to pollen? Any expansion to mold, other particles? – Mr. Johnson agreed that there is potential to teach the AI to identify molds. Just beginning that work. Indoors too. Relatively inexpensive instrumentation. Chairman Morrison suggested it could drive a lot in construction in ventilation.

#### Item 9. FINANCIAL REPORT

Kevin Karbowski

Decrease in OHD and Non-Covid Clinical activity, negative to budget by \$600,000. About half of clinical shortfall is less non-Covid activity from APHL. \$200,000. The remaining 200k is spread out.

Budget – Preliminary budget for next year to submit for approval in June 1.5M and half Million – Due to increased costs in NBS, which we haven't seen a price increase in over 10 years – We have a lot of work to do in budget meetings for June.

- Expecting \$500,000 shortfall largely due to newborn shortfall
- Requesting 6% price increase (fee for service) in 2023 to cover salary costs. First price increase since 5% in 2019.
- Across the board increase with individual exceptions some programs might need a little more or less. 6% nominal.

For test pricing or budget overall. Price increase needed most in NBS, but we have no control. This would be price service increases for customers, to match what we've paid staff.

Mr. Kindrai: Anywhere that drives market capacity demand rather than across the board? Mr. Karbowski advises that "across the board is where we have control and can increase prices." Nominal 6%: In some cases, it could be more or less.

Chairman Morrison: Entertain motion for price increase discussion: Mr. Kindrai moves to authorize nominal 6% increase – Greg Pils seconds Discussion:

What WSLH does is take the current price, increase on spreadsheet by 6% and look at it, line by line, with managers, to make sure that 6% is the right thing to do for each of these individual tests. If a reagent has doubled, WSLH may have to alter the price.

Transportation looks like it's going to be an issue –WSLH only asks for price increases when we actually need it.

Shortfall to address NBS – Any increase will improve overall NBS Screening; it won't impact our loss Will this increase help offset the Newborn Screening losses? This is complicated by existing contracts, so the price increase will take a while to kick in but should represent about a 2% increase in revenue.

Dr. Schauer advises we are still seeking budget and efficiency improvements going forward, but we are bottlenecked in accessioning and data entry. IT resolutions are not trivial but it's probably the way forward. Bar coding and automated scanning data collections.

Mr. Kindrai makes the motion to approve an increase in fees of 6%: Unanimous in favor, none opposed.

Mr. Karbowski advises that, by statute, we advise of all contracts we enter into for services and those are displayed in the financial slides. Signed 6.3M contracts mostly with ELC.

#### Item 10. HR UPDATE

Cynda absent, presented by Secretary, Jamie Schauer

Cynda is one of the retirements listed, at the end of April – Leadership change is happening at this time 12 new employees 9 internal changes, 6 retirements, 4 resignations – Some positions are reaching two-year maximums as well.

#### Item 11. DIRECTOR'S REPORT

- Water Boil Notice Report
  - Dave Webb
     3 in Door County, 1 in Grant, possibly more to come with springtime rains
- UCMR<sub>5</sub> Update
  - o Dave Webb

Thanks to those who participated in constructive meeting – Dynamic PFAS environment – A lot of labs not formally approved, two more PTs – Previously mentioned EPA-sponsored seminars - When/if we are approved, it will be in April. There are lots of internal conversations happening and WSLH chose not to pursue the small public water systems; the administrative burden is not in our wheelhouse. RT Krueger's lab will be able to handle those; if/when we get on the list, we will be able to accept large public water systems. Mr. Webb advised he had a good conversation with Mr. Krueger a week ago.

- Public Relations Report
  - o Jan Klawitter
    - Media coverage NBS COVID, sewage water, influenza screening
    - Highlights of employees and their accomplishments.

Environmental microbiology becoming more about waste water for influenza. Covid wastewater testing continues.

Newborn Services was recently in the news with several articles

Heather Barkholtz - new grant for testing strategies for items like bath salts to enable rapid identification

SMPH published quarterly magazine - two recent stories on WSLH.

Ms. Klawitter referred Board Members to the packet which provides details and further information about more employee activities and accomplishments.

#### Item 12. ELECTIONS OF OFFICERS

Chairman Morrison will be stepping down in June

Governmental and Non-Governmental categories.

Greg Pils is Governmental, replacing Jim Morrison (Non-governmental). Dr. Gonzalez would be willing. Dr. Corliss, Ms. Green Harris and Dr. Gonzalez are the eligible parties.

Elect Vice Chair – Nominate Dr. Corliss or Dr. Gonzalez (who is not present)

Motion to nominate Mr. Pils for Chair, Dr. Corliss for Vice Chair, Dr. Schauer for Secretary. Dr. Meiman seconded. None opposed.

Motion: Mr. Pils making a motion to nominate Dr. Robert Corliss for next term.

Mr. Kindrai: Moves for the nomination of the following for officers of the WSLH Board of Directors: Greg Pils for the position of Chair, Robert Corliss for the position of Vice-Chair/Chair-Elect, and James Schauer for the position of Secretary for the year 2022 term.

The motion was seconded by Jon Meiman

No discussion – Motion passed unanimously.

Mr. Jim Morrison was thanked for his service and guidance as Chair and requested to keep in touch with WSLH. Mr. Morrison responded that WSLH is well-respected and does outstanding work. It was a pleasure to serve and he looks forward to WSLH's future success.

Vice Chair Greg Pils made a motion to adjourn the meeting at 2:45 P.M. Mr. Kindrai seconded the motion. The motion passed unanimously and the meeting was adjourned.

Respectfully submitted by:

James J. Schauer, PhD, P.E., M.B.A.

Ja Ja Soli

Secretary, Wisconsin State Laboratory of Hygiene Board of Directors

#### **PROCEDURAL ITEMS**

#### Item 3. REORGANIZATION OF AGENDA

#### **Description of Item:**

Board members may suggest changes in the order in which agenda items are discussed

#### **Suggested Board Action:**

None

## **Staff Recommendation and Comments:**

Reorganize the agenda if requested by the Board

#### **PROCEDURAL ITEMS**

#### Item 4. PUBLIC APPEARANCES

#### Description of Item:

Under the board's Policies and Procedures, nonmembers are invited to make presentations

#### **Suggested Board Action:**

Follow WSLH Policies and Procedures

#### Staff Recommendation and Comments:

Follow WSLH Policies and Procedures

Per Policies and Procedures of the Wisconsin State Laboratory of Hygiene Board of Directors:

- §6.12 Speaking privileges. When the board is in session, no persons other than laboratory staff designated by the director shall be permitted to address the board except as hereinafter provided:
  - (a) A committee report may be presented by a committee member who is not a member of the board.
  - (b) A board or committee member in the course of presenting a matter to the board may request staff to assist in such a presentation.
  - (c) If a board member directs a technical question for clarification of a specific issue to a person not authorized in this section, the Chair may permit such a person to respond.
  - (d) The board may by majority vote or by decision of the Chair allow persons not otherwise authorized in this section to address the board if the situation warrants or the following criteria is followed:
    - (1) Written requests for public appearances on specific current agenda items shall be made to the board Secretary no later than two working days prior to the meetings. The request shall outline the reasons for the request including the subject matter to be discussed in as much detail as is feasible prior to the meeting of the board. Those requesting an appearance may, at or prior to the board meeting, provide board members copies of any written materials to be presented or a written statement of a position.
    - (2) Individual presentations will be limited to five minutes, unless otherwise authorized by the
    - (3) To schedule an appearance before the Wisconsin State Laboratory of Hygiene Board of Directors, contact the board Secretary, c/o Director, Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Madison, Wisconsin 53706. Telephone (608) 890-0288. The subject or subjects to be discussed must be identified.
    - (4) The Wisconsin State Laboratory of Hygiene "Guidelines for Citizen Participation in WSLH Board Meetings" are published on its website: http://www.slh.wisc.edu/index.shtml and printed copies are available on request. (See Appendix 5) [Section §6.12 approved 5/27/03 board meeting.]

#### Appendix 5

#### **Guidelines for Citizen Participation at WSLH Board Meetings**

The Wisconsin State Laboratory of Hygiene board provides opportunities for citizens to appear before the board to provide information to the board on items listed on the agenda. Such appearances shall be brief and concise. In order to accommodate this participation in the allotted time, the guidelines are as follows:

- A. Items to be brought before the board:
  - 1. The board Secretary and Chair will assign a specific time on the agenda to hear public comment when a request to speak has been received from a member of the public.
  - 2. Individuals or organizations will be limited to a total of five (5) minutes to make a presentation to the board. Following the presentation board members may ask clarifying questions.
  - 3. An organization is limited to one (1) spokesperson on an issue.
  - 4. On complex issues, individuals wishing to appear before the board are encouraged to submit written materials to the board Secretary in advance of the meeting so the board may be better informed on the subject in question. Such information should be submitted to the board Secretary for distribution to all board members no later than seven (7) working days before the board meeting.
  - 5. No matters that are in current litigation may be brought before the board.
- B. The board encourages individuals to confine their remarks to broad general policy issues rather than the day-to-day operations of the Wisconsin State Laboratory of Hygiene.
- C. Citizens who have questions for board members should ask these questions prior to the board meeting, during any recess during the board proceedings, or after board adjournment.
- D. Written requests to appear before the WSLH Board of Directors should be submitted <u>no later than two (2)</u> working days prior to a scheduled board meeting.
- E. Submit written requests to: Secretary, Wisconsin State Laboratory of Hygiene Board of Directors

C/O WSLH Director 465 Henry Mall Madison, WI 53706

Telephone: (608) 890-0288

Email: susan.buechner@slh.wisc.edu

#### **PROCEDURAL ITEMS**

#### Item 5. BOARD MEMBERS' MATTERS

#### **Description of the Item:**

Board Members' Matters will present board members with the opportunity to ask questions and/or discuss issues related to the Wisconsin Laboratory of Hygiene

#### **Suggested Board Action:**

Receive for information

#### **Staff Recommendations and Comments:**

Receive for information

#### **BUSINESS ITEMS:**

Item 6. WISCONSIN'S OPIOID EPIDEMIC

#### **Description of Item:**

Paul Krupski, Director of Opiate Initiatives, Wisconsin Department of Health Services, will provide the Trends in Opioid Overdoses and Deaths in Wisconsin presentation to the Board.

#### **Suggested Board Action:**

Review and provide input.

#### **Staff Recommendation and Comments:**

Receive for information

#### **BUSINESS ITEMS**

#### Item 7. ROLE OF PHARMACIES IN FUTURE POINT OF CARE TESTING

#### Description of the Item:

#### Dr. Casey Gallimore

University of Wisconsin-Madison Associate Professor / Co-Director of the Interprofessional Education Program at the University of Wisconsin-Madison School of Pharmacy

&

#### Dr. Andrea Porter

University of Wisconsin-Madison Associate Professor (CHS) / Director of Pharmacotherapy Laboratories, University of Wisconsin-Madison School of Pharmacy

will provide a presentation on the Role of Pharmacies in future Point of Care Testing

#### **Suggested Board Action:**

Review and provide input

#### **Staff Recommendations and Comments:**

Receive for information

#### **BUSINESS ITEMS**

#### Item 8. FINANCIAL REPORT

#### **Description of the Item:**

Kevin Karbowski, WSLH Chief Financial Officer, will provide an update on the Financial Report to the Board.

#### **Suggested Board Action:**

Review and provide input.

#### **Staff Recommendations and Comments:**

Receive for information.

#### WISCONSIN STATE LABORATORY OF HYGIENE

FINANCIAL REPORT

FISCAL YEAR 2022

April 30, 2022

#### Contents

#### FINANCIAL STATEMENTS

Statement of income

Comparative income statement

Comparative balance sheet

Statement of cash flows

Notes to the financial statements

#### WISCONSIN STATE LABORATORY OF HYGIENE STATEMENT OF INCOME For the period July 1, 2021 through April 30, 2022

SUPPORT AND REVENUE	Year to Date Actual	Year to Date Budget	Variance Over/(Under)	Variance % of Budget	Fiscal Year 2022 Annual Budget
Clinical	\$15,676,544	\$16,695,624	(\$1,019,080)		\$20,324,657
Newborn Screening	3,477,350	3,540,330	(62,980)	-1.8%	4,300,000
Driver Improvement Surcharge	1,381,135	1,352,979	28,156	2.1%	1,619,200
Environmental	5,008,187	5,152,954	(144,767)	-2.8%	5,984,085
National Atmosphoric Deposition Program	1,325,862	1,437,727	(111,864)	-7.8%	1,777,308
Proficiency	2,591,716	2,778,232	(186,516)	-6.7%	3,433,738
Occupational Health	1,579,384	1,809,469	(230,085)	-12.7%	2,156,557
Laboratory Services	31,040,179	32,767,314	(1,727,136)	-5.3%	39,595,545
Fund 150 Support	745,221	837,506	(92,285)	-11.0%	1,005,007
WIDHS Employee Contracts	684,622	718,973	(34,350)	-4.8%	862,767
Earnings - Investment Income	2,324	5,300	(2,976)	-56.2%	6,000
Other Revenue	1,432,167	1,561,778	(129,611)	-8.3%	1,873,774
Sponsored Projects	5,243,179	5,195,812	47,367	0.9%	6,204,641
Program Revenue	37,715,524	39,524,905	(1,809,380)	-4.6%	47,673,960
State General Program Revenue (GPR)	9,749,838	9,705,493	44,345	0.5%	11,820,000
TOTAL SUPPORT AND REVENUE	47,465,362	49,230,398	(1,765,035)	-3.6%	59,493,960
EXPENSES					
Salaries	18,718,252	18,629,067	89,185	0.5%	23,186,967
Fringe Benefits	7,199,530	7,310,367	(110,836)	-1.5%	8,519,989
Supplies & Services	17,183,933	17,802,189	(618,256)	-3.5%	21,578,848
Building Rent	2,702,886	2,695,679	7,208	0.3%	3,330,756
Transfer Overhead to UW	804,571	834,431	(29,860)	-3.6%	1,017,487
Depreciation	2,017,033	2,049,551	(32,519)	-1.6%	2,474,948
Bad Debt Expense	459	3,000	(2,541)		3,600
Interest Expense	409	5,000	(4,591)	-91.8%	6,000
TOTAL EXPENSES	48,627,074	49,329,284	(702,210)	-1.4%	60,118,594
NET OPERATING INCOME (LOSS)	(\$1,161,712)	(\$98,886)	(\$1,062,826)		(\$624,634)

# WISCONSIN STATE LABORATORY OF HYGIENE COMPARATIVE INCOME STATEMENT For the 10 months ended April 30, 2022 and April 30, 2021

SUPPORT AND REVENUE	Year to Date Actual	Prior Year Actual	Variance Over/(Under)	Variance % of Budget
Clinical	\$15,676,544	\$15,667,611	\$8,933	0.1%
Newborn Screening	3,477,350	3,620,097	(142,747)	
Driver Improvement Surcharge	1,381,135	1,398,899	(17,764)	
Environmental	5,008,187	4,128,857	879,330	21.3%
National Atmosphoric Deposition Program	1,325,862	1,370,032	(44,170)	-3.2%
Proficiency	2,591,716	2,727,801	(136,085)	
Occupational Health	1,579,384	1,306,643	272,741	20.9%
Laboratory Services	31,040,179	30,219,940	820,239	2.7%
Fund 150 Support	745,221	795,197	(49,976)	-6.3%
WIDHS Employee Contracts	684,622	792,482	(107,860)	
Earnings - Investment Income	2,324	5,829	(3,505)	-60.1%
Other Revenue	1,432,167	1,593,509	(161,342)	-10.1%
Sponsored Projects	5,243,179	4,437,929	805,250	18.1%
Program Revenue	37,715,524	36,251,377	1,464,147	4.0%
State General Program Revenue (GPR)	9,749,838	9,579,044	170,794	1.8%
TOTAL SUPPORT AND REVENUE	47,465,362	45,830,421	1,634,941	3.6%
EXPENSES				
Salaries	18,718,252	18,179,132	539,120	3.0%
Fringe Benefits	7,199,530	7,053,949	145,581	2.1%
Supplies & Services	17,183,933	16,309,607	874,326	5.4%
Building Rent	2,702,886	2,604,610	98,276	3.8%
Transfer Overhead to UW	804,571	797,577	6,994	0.9%
Depreciation	2,017,033	1,693,315	323,718	19.1%
Bad Debt Expense	459	1,751	(1,292)	
Interest Expense	409	1,350	(941)	-69.7%
TOTAL EXPENSES	48,627,074	46,641,291	1,985,783	4.3%
NET OPERATING INCOME (LOSS)	(\$1,161,712)	(\$810,870)	(\$350,842)	43.3%

# WISCONSIN STATE LABORATORY OF HYGIENE COMPARATIVE BALANCE SHEET As of April 30, 2022 and June 30, 2021

CURRENT ASSETS         April 30, 2022         June 30, 2021           Cash - restricted (Note 1)         \$2,193,122         \$3,202,501           Cash - restricted (Note 1)         4,178,033         4,031,415           Net accounts receivables (Note 2)         6,165,013         5,696,761           Other receivables         777,441         912,602           Inventories         51,478         39,107           Prepaid expenses         49,636         264,896           Total current assets         13,414,724         14,147,282           EQUIPMENT AND BUILDING IMPROVEMENTS         Equipment         35,485,485         33,123,260           Building improvements         6,878,228         6,878,228         6,878,228           Building improvements         6,878,228         6,878,228         27,925,329           Total net fixed assets         12,421,352         12,076,159           Total net fixed assets         12,421,352         12,076,159           Total Assets         \$25,836,076         \$26,223,442           CURRENT LIABILITIES         \$0         \$0           Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$1,425,142         845,108           Accounts payable         \$1,213,414 <th>ASSETS</th> <th>A</th> <th>l 00 0004</th>	ASSETS	A	l 00 0004
Cash (Cash-restricted (Note 1)         \$2,193,122         \$3,202,501           Cash-restricted (Note 1)         4,178,033         4,031,415           Net accounts receivables (Note 2)         6,165,013         5,696,761           Other receivables         777,441         912,602           Inventories         51,478         39,107           Prepaid expenses         49,636         264,896           Total current assets         13,414,724         14,147,282           EQUIPMENT AND BUILDING IMPROVEMENTS         Equipment         35,485,485         33,123,260           Building improvements         6,878,228         6,678,228         6,678,228           Building improvements         42,363,713         40,001,488         42,363,713         40,001,488           Less accumulated depreciation         (29,942,362)         (27,925,329)         Total net fixed assets         12,421,352         12,076,159           Total net fixed assets         12,421,352         12,076,159         Total Assets         \$0         \$0           CURRENT LIABILITIES         381eries and fringe benefits payable         \$0         \$0         \$0           Accounts payable         1,425,142         845,108         Accrued expenses         82,165         0         0           Defe	CURRENT ASSETS	April 30, 2022	June 30, 2021
Cash-restricted (Note 1)         4,178,033         4,031,415           Net accounts receivables (Note 2)         6,165,013         5,696,761           Other receivables         777,441         912,602           Inventories         51,478         39,107           Prepaid expenses         49,636         264,896           Total current assets         13,414,724         14,147,282           EQUIPMENT AND BUILDING IMPROVEMENTS         26,878,228         3,3123,260           Building improvements         6,878,228         6,878,228         6,878,228           Less accumulated depreciation         (29,342,362)         (27,925,329)           Total net fixed assets         12,421,352         12,076,159           Total Assets         \$25,836,076         \$26,223,442           LIABILITIES         Salaries and fringe benefits payable         \$0         \$0           Accounts payable         1,425,142         845,108           Accrued expenses         82,165         0           Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         6,897,654		¢2 103 122	¢3 202 501
Net accounts receivables (Note 2)         6,165,013         5,696,761           Other receivables         777,441         912,602           Inventories         51,478         39,107           Prepaid expenses         49,636         264,896           Total current assets         13,414,724         14,147,282           EQUIPMENT AND BUILDING IMPROVEMENTS         35,485,485         33,123,260           Building improvements         6,878,228         6,878,228           Building improvements         42,363,713         40,001,488           Less accumulated depreciation         (29,942,362)         (27,925,329)           Total net fixed assets         12,421,352         12,076,159           Total Assets         \$25,836,076         \$26,223,442           LACA sects         \$25,836,076         \$26,223,442           LACA sects         \$25,836,076         \$26,223,442           LACA sects         \$2,6223,442         \$2,6123,442           LACA sects         \$2,6223,442         \$2,6123,442           CURRENT LIABILITIES         \$2,6123,442         \$2,6123,442           Salaries and fringe benefits payable         \$0         \$0           Accrude expenses         \$2,165         0           Deferred revenue         0 <td></td> <td></td> <td></td>			
Other receivables Inventories         777,441         912,602 Inventories         39,107 Prepaid expenses         49,636         264,896           Total current assets         13,414,724         14,147,282         264,896           EQUIPMENT AND BUILDING IMPROVEMENTS         5,485,485         33,123,260           Building improvements         6,878,228         6,878,228           Less accumulated depreciation         (29,942,362)         (27,925,329)           Total net fixed assets         12,421,352         12,076,159           Total Assets         \$25,836,076         \$26,223,442           LACCURTENT LIABILITIES         Salaries and fringe benefits payable         \$0         \$0           Accourts payable         1,425,142         845,108           Accrued expenses         82,165         0           Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664			
New Notice   1,478   39,107   Prepaid expenses   49,636   264,89	• • • • • • • • • • • • • • • • • • • •		
Prepaid expenses         49,636         264,896           Total current assets         13,414,724         14,147,282           EQUIPMENT AND BUILDING IMPROVEMENTS         Equipment         35,485,485         33,123,260           Building improvements         6,878,228         6,878,228         6,878,228           Less accumulated depreciation         (29,942,362)         (27,925,329)           Total net fixed assets         12,421,352         12,076,159           Total Assets         \$25,836,076         \$26,223,442           LIABILITIES AND EQUITY         Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$0         \$0           Accounts payable         \$0         \$0           Accrued expenses         \$2,165         0           Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         1,661,462         1,657,664           Total long term debt         1,661,462	Inventories	•	•
EQUIPMENT AND BUILDING IMPROVEMENTS           Equipment         35,485,485         33,123,260           Building improvements         6,878,228         6,878,228           Less accumulated depreciation         (29,942,362)         (27,925,329)           Total net fixed assets         12,421,352         12,076,159           Total Assets         \$25,836,076         \$26,223,442           CURRENT LIABILITIES           Salaries and fringe benefits payable         \$0         \$0           Accounts payable         1,425,142         845,108           Accounts payable         1,425,142         845,108           Accrued expenses         82,165         0           Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total liabilities         \$8,559,116	Prepaid expenses		•
Equipment         35,485,485         33,123,260           Building improvements         6,878,228         6,878,228           42,363,713         40,001,488           Less accumulated depreciation         (29,942,362)         (27,925,329)           Total net fixed assets         12,421,352         12,076,159           Total Assets         \$25,836,076         \$26,223,442           LIABILITIES         \$0         \$0           Salaries and fringe benefits payable         \$0         \$0           Accounts payable         1,425,142         845,108           Accrued expenses         82,165         0           Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         6,897,654         6,127,106           LONG TERM DIETS         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Position de deam	Total current assets	13,414,724	14,147,282
Building improvements	EQUIPMENT AND BUILDING IMPROVEMENTS		
A2,363,713	Equipment	35,485,485	33,123,260
Less accumulated depreciation         (29,942,362)         (27,925,329)           Total net fixed assets         12,421,352         12,076,159           Total Assets         \$25,836,076         \$26,223,442           LIABILITIES AND EQUITY         \$0         \$0           CURRENT LIABILITIES         \$0         \$0           Salaries and fringe benefits payable         \$0         \$0           Accounts payable         1,425,142         845,108           Accrued expenses         82,165         0           Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156	Building improvements	6,878,228	6,878,228
Total net fixed assets         12,421,352         12,076,159           Total Assets         \$25,836,076         \$26,223,442           LIABILITIES AND EQUITY           CURRENT LIABILITIES           Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$1,425,142         845,108           Accrued expenses         \$2,165         \$0           Deferred revenue         \$0         \$252,619           Compensated absences (Note 3)         \$1,212,314         \$997,964           Proficiency testing deferred revenue         \$1,718,314         \$1,024,366           Newborn screening surcharge payable         \$0         696,929           Total current liabilities         \$6,897,654         \$6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         \$1,661,462         \$1,657,664           Total long term debt         \$1,661,462         \$1,657,664         \$7,784,770           EQUITY           Net Operating Income (Loss)         \$1,280,4156         \$2,641,428           Contributed capital         \$5,634,516         \$5,634,516           Total retained earnings         \$17,276,960         \$18,438,672           Total Equity         \$17,276,960         \$18		42,363,713	40,001,488
Total Assets   \$25,836,076   \$26,223,442	Less accumulated depreciation	(29,942,362)	(27,925,329)
LIABILITIES AND EQUITY           CURRENT LIABILITIES           Salaries and fringe benefits payable         \$0         \$0           Accounts payable         1,425,142         845,108           Accrued expenses         82,165         0           Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           T	Total net fixed assets	12,421,352	12,076,159
CURRENT LIABILITIES           Salaries and fringe benefits payable         \$0         \$0           Accounts payable         1,425,142         845,108           Accrued expenses         82,165         0           Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672 <td>Total Assets</td> <td>\$25,836,076</td> <td>\$26,223,442</td>	Total Assets	\$25,836,076	\$26,223,442
Salaries and fringe benefits payable         \$0         \$0           Accounts payable         1,425,142         845,108           Accrued expenses         82,165         0           Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	LIABILITIES AND EQUITY		
Accounts payable       1,425,142       845,108         Accrued expenses       82,165       0         Deferred revenue       0       252,619         Compensated absences (Note 3)       1,212,314       997,964         Proficiency testing deferred revenue       1,718,314       1,024,366         Newborn screening deferred revenue       2,459,720       2,310,120         Newborn screening surcharge payable       0       696,929         Total current liabilities       6,897,654       6,127,106         LONG TERM DEBT       Compensated Absences (Note 3)       1,661,462       1,657,664         Total long term debt       1,661,462       1,657,664         Total Liabilities       \$8,559,116       \$7,784,770         EQUITY         Net Operating Income (Loss)       (1,161,712)       189,728         Retained earnings       12,804,156       12,614,428         Contributed capital       5,634,516       5,634,516         Total retained earnings       17,276,960       18,438,672         Total Equity       17,276,960       18,438,672	CURRENT LIABILITIES		
Accrued expenses       82,165       0         Deferred revenue       0       252,619         Compensated absences (Note 3)       1,212,314       997,964         Proficiency testing deferred revenue       1,718,314       1,024,366         Newborn screening deferred revenue       2,459,720       2,310,120         Newborn screening surcharge payable       0       696,929         Total current liabilities       6,897,654       6,127,106         LONG TERM DEBT       Compensated Absences (Note 3)       1,661,462       1,657,664         Total long term debt       1,661,462       1,657,664         Total Liabilities       \$8,559,116       \$7,784,770         EQUITY         Net Operating Income (Loss)       (1,161,712)       189,728         Retained earnings       12,804,156       12,614,428         Contributed capital       5,634,516       5,634,516         Total retained earnings       17,276,960       18,438,672         Total Equity       17,276,960       18,438,672	Salaries and fringe benefits payable	\$0	\$0
Deferred revenue         0         252,619           Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         5         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	Accounts payable	1,425,142	845,108
Compensated absences (Note 3)         1,212,314         997,964           Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	Accrued expenses	82,165	0
Proficiency testing deferred revenue         1,718,314         1,024,366           Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	Deferred revenue	0	252,619
Newborn screening deferred revenue         2,459,720         2,310,120           Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	Compensated absences (Note 3)	1,212,314	997,964
Newborn screening surcharge payable         0         696,929           Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	Proficiency testing deferred revenue	1,718,314	1,024,366
Total current liabilities         6,897,654         6,127,106           LONG TERM DEBT         Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	Newborn screening deferred revenue	2,459,720	2,310,120
LONG TERM DEBT         Compensated Absences (Note 3)       1,661,462       1,657,664         Total long term debt       1,661,462       1,657,664         Total Liabilities       \$8,559,116       \$7,784,770         EQUITY         Net Operating Income (Loss)       (1,161,712)       189,728         Retained earnings       12,804,156       12,614,428         Contributed capital       5,634,516       5,634,516         Total retained earnings       17,276,960       18,438,672         Total Equity       17,276,960       18,438,672	Newborn screening surcharge payable	0	696,929
Compensated Absences (Note 3)         1,661,462         1,657,664           Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	Total current liabilities	6,897,654	6,127,106
Total long term debt         1,661,462         1,657,664           Total Liabilities         \$8,559,116         \$7,784,770           EQUITY           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672			
Total Liabilities         \$8,559,116         \$7,784,770           EQUITY         Sequity         189,728           Net Operating Income (Loss)         (1,161,712)         189,728           Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	Compensated Absences (Note 3)	1,661,462	1,657,664
EQUITY         Net Operating Income (Loss)       (1,161,712)       189,728         Retained earnings       12,804,156       12,614,428         Contributed capital       5,634,516       5,634,516         Total retained earnings       17,276,960       18,438,672         Total Equity       17,276,960       18,438,672	Total long term debt	1,661,462	1,657,664
Net Operating Income (Loss)       (1,161,712)       189,728         Retained earnings       12,804,156       12,614,428         Contributed capital       5,634,516       5,634,516         Total retained earnings       17,276,960       18,438,672         Total Equity       17,276,960       18,438,672	Total Liabilities	\$8,559,116	\$7,784,770
Retained earnings         12,804,156         12,614,428           Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	EQUITY		
Contributed capital         5,634,516         5,634,516           Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672		(1,161,712)	189,728
Total retained earnings         17,276,960         18,438,672           Total Equity         17,276,960         18,438,672	<u> </u>	12,804,156	12,614,428
Total Equity 17,276,960 18,438,672	Contributed capital	5,634,516	5,634,516
	Total retained earnings	17,276,960	18,438,672
Total Liabilities and Equity         \$25,836,076         \$26,223,442	Total Equity	17,276,960	18,438,672
	Total Liabilities and Equity	\$25,836,076	\$26,223,442

# WISCONSIN STATE LABORATORY OF HYGIENE STATEMENT OF CASH FLOWS

For the 10 months ended April 30, 2022 and June 30, 2021

	Year to Date	Prior Year
ASH FLOWS FROM OPERATING ACTIVITIES		
Net income	(\$1,161,712)	\$189,728
Adjustments to reconcile net income to net cash provided by operating		
activities:		
Depreciation	2,017,033	2,026,375
Changes in working capital components:		
Decrease/(Increase) in net accounts receivables	(468,252)	(1,862,839
Decrease/(Increase) in other receivables	135,161	(17,860
Decrease/(Increase) in inventories	(12,371)	2,332
Decrease/(Increase) in prepaid expenses	215,260	(170,412
(Decrease)/Increase in salaries payable	0	(
(Decrease)/Increase in accounts payable	580,034	393,248
(Decrease)Increase in accrued expenses	82,165	(78,194
(Decrease)Increase in deferred revenue	(252,619)	249,424
(Decrease)Increase in proficiency testing deferred revenue	693,947	(102,66
(Decrease)/Increase in newborn screen deferred revenue	149,600	(114,879
(Decrease)/Increase in newborn screening surcharge payable	(696,929)	(290,660
Net cash provided (used) in operating activities	1,281,316	223,597
ASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of equipment and physical plant improvements	(2,144,077)	(3,033,294
Net cash provided (used) in investing activities	(2,144,077)	(3,033,294
ASH FLOWS FROM FINANCING ACTIVITIES		
Principal payment on Capital Lease	-	
Net cash provided (used) in financing activities	-	
Net increase (decrease) in cash	(862,761)	(2,809,697
ash:		
Beginning	7,233,916	10,043,613
Ending	\$6,371,156	\$7,233,916

# WISCONSIN STATE LABORATORY OF HYGIENE

#### NOTES TO THE FINANCIAL STATEMENTS

For the period July 1, 2021 through April 30, 2022

#### NOTE 1 - NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

#### Nature of Business:

- The Wisconsin State Laboratory of Hygiene (WSLH) is a governmental institution which provides medical, industrial and environmental laboratory testing and related services to individuals, private and public agencies, including the Department of Natural Resources (DNR) and the Department of Health Services (DHS). Approximately 75% of the WSLH operating revenues are program revenues, including contracts, grants, and fee-for-service billing. The remainder are general purpose revenues (GPR), which are Wisconsin state general fund dollars.

#### **Budgetary Data:**

- Fiscal Year 2021-2022 operating budget amounts were approved by the WSLH Board on June 22, 2021.

#### Basis of Presentation:

- The financial statements have been prepared on a modified accrual basis following Generally Accepted Accounting Principles (GAAP).

#### **Basis of Accounting:**

- Revenues are recognized at the completion of the revenue generating processes. Fee-for-service revenues are generally recognized in the period services are completed.
- Revenues from GPR, OWI, Grants, and expense reimbursement contracts for salaries, fringe benefits, capital, and supplies are recognized as expended.
- Expenses are recognized and accrued when the liability is incurred.

#### Estimates and assumptions:

- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying footnotes. Actual results could differ from those estimates.

#### <u>Assets</u>

- As of April 30, 2022 cash is restricted to the newborn screening surcharge payable, to the proficiency testing deferred revenue and to the newborn screening deferred revenue.
- Accounts receivable are reported at net realizable value. Net realizable value is equal to the gross amount of receivables less an estimated allowance for uncollectible amounts.
- Inventory is stated at cost (first in, first-out method).

- Equipment and building improvements are carried at cost. Expenditures for assets in excess of \$5,000 are capitalized. Depreciation is computed by the straight-line method.

#### **Liabilities**

A liability for unearned revenue is recognized for prepaid receipts for WSLH-provided proficiency testing programs and for prepaid newborn screening tests.

#### **NOTE 2 - ACCOUNTS RECEIVABLE**

 Accounts receivable and allowance for uncollectible account balances as of April 30, 2022 and June 30, 2021 are as follows:

	April 30, 2022	June 30, 2021
Accounts Receivable Total	\$6,251,354	\$5,786,045
Allowance for bad debt	(86,341)	(89,284)
Net Receivables	\$6,165,013	\$5,696,761

#### **NOTE 3 - COMPENSATED ABSENCES**

GASB Statement No. 16, "Accounting for Compensated Absences," establishes standards of accounting and reporting for compensated absences by state and local governmental entities for which employees will be paid such as vacation, sick leave, and sabbatical leave. Using the criteria in Statement 16, a liability for compensated absences that is attributable to services already rendered and that is not contingent on a specific event that is outside the control of the State and its employees has been accrued. The table below details the liability by benefit category:

	Total	Vacation	Pers Hol	Legal Hol	Sabbatical
Current	\$1,212,314	\$966,250	\$75,210	\$25,248	\$145,606
Long Term	1,661,462				1,661,462
-	\$2,873,776	\$966,250	\$75,210	\$25,248	\$1,807,068

#### **BUSINESS ITEMS**

#### Item 9. APPROVAL OF FY23 BUDGET

#### **Description of the Item:**

Kevin Karbowski, WSLH Chief Financial Officer, will present the FY23 Budget approval to the Board.

#### **Suggested Board Action:**

Review and provide input.

#### **Staff Recommendations and Comments:**

Receive for information.

Fiscal Year 2023 Budget	
Income Statement	
State Laboratory of Hygiene	
Twelve Months ending June 30, 2023	

Support and Revenue	Fiscal Year 2023 Budget Accrual	Fiscal Year 2023 Budget Cash
State General Program Revenue	\$12,142,000	\$12,142,000
WI Driver Improvement Surcharge	1,619,200	1,619,200
Clinical	18,737,386	18,737,386
WI Newborn Screening	4,150,000	4,150,000
Environmental	9,227,908	9,227,908
Proficiency Testing	4,155,130	4,155,130
Occupational Health	2,156,557	2,156,557
WDHS Employee Contracts	862,767	862,767
Earning-Investment Income	6,000	6,000
Sponsored Projects	5,567,503	5,567,503
Federal Indirect Cost Reimbursement	852,000	852,000
Total Support and Revenue	59,476,451	59,476,451
Expenses		
Salaries	23,744,222	23,744,222
Fringe Benefits	8,888,568	8,888,568
Supplies and Services	21,544,614	21,544,614
Transfer-Ovrhead Allow-133&144	921,135	921,135
Building Rent	3,207,003	3,207,003
Depreciation	2,551,635	0
Capital	0	2,105,421
Bad Debt Expense	3,600	3,600
Interest Expense	3,600	3,600
Total Expenses	60,864,375	60,418,162
Net Operating Income/(Loss)	(\$1,387,924)	(\$941,711)

#### **BUSINESS ITEMS**

#### Item 10. CONTRACTS REPORT

#### **Description of the Item:**

Kevin Karbowski, WSLH Chief Financial Officer, will provide an update on the Contracts Report to the Board.

#### **Suggested Board Action:**

Review and approve budget.

#### **Staff Recommendations and Comments:**

Receive for information.

University of Wisconsin-Madison Wisconsin State Laboratory of Hygiene Summary of Contracts Executed Since March 2022 Board Meeting				
Title	Party	Award Amount	Timeframe	
Chemical Level One Laboratory	WDHS	\$ 1,445,235	over 12 mos.	
Biological Response Capacity	WDHS	689,885	over 12 mos.	
Radiation Protective Services	WDHS	128,526	over 12 mos.	
Tuberculosis Elimination	WDHS	118,432	over 12 mos.	
Public Health Emergency Preparedness Base	WDHS	106,620	over 12 mos.	
HIV Testing CY2022	WDHS	10,534	over 12 mos.	
Health Care Education & Training Colposcopy	HCET	10,000	over 6 mos.	
Total		\$ 2,509,232		

#### **BUSINESS ITEMS**

#### Item 11. DIRECTOR'S REPORT

Dr James Schauer, Director, WSLH

- Strategic Plan Update
  - Kevin Karbowski
- Water Boil Notice Report
  - Dave Webb
- PFAS Testing
  - o Dave Webb
- Space Update
  - o Dave Webb
- Monkeypox Testing
  - o Dr. Alana Sterkel
- Public Relations Report
  - o Jan Klawitter

#### Item 11. DIRECTOR'S REPORT

Water Boil Notice ReportDave Webb

Report to the Wisconsin State Laboratory of Hygiene Board

Water Systems Tests by the WSLH

March 1, 2022 – June 1, 2022

COUNTY_NAME	PWS_TYPE	NUMBER_OF_SYSTEMS	NUMBER_OF_UNSAFE	NUMBER_OF_BWO
Door	TN	236	9	3

#### Item 11. DIRECTOR'S REPORT

- Public Relations Report
  - Jan Klawitter

## Report to the Wisconsin State Laboratory of Hygiene Board

#### Representative Public or Environmental Health Incidents of Educational Interest

#### March 3, 2022 – June 10, 2022

Approx. Date	Agent or Event Name	Description	Current Status
		OUTBREAKS and INCIDENTS	
January 2020	COVID-19 virus	The WSLH's COVID-19 pandemic response efforts and collaborations with WI DHS, CDC, UW-Madison, UW-Milwaukee, WI Clinical Laboratory Network hospital laboratories and others are ongoing, including:  Outbreak (patient) testing Wastewater surveillance Whole-genome sequencing of SARS-CoV-2 viruses for strain surveillance and variant detection statewide COVID-19 consultation services for WI businesses seeking to improve their facility's employee protection plans and procedures related to COVID-19 Providing respirator fit testing kits, training, and related assistance to employees at over 4,500 nursing and residential care facilities throughout the state.	Ongoing
May 2022	Monkeypox virus	An international monkeypox outbreak was identified in May 2022. The WSLH Communicable Disease Division has been in close contact with the WI DHS/DPH Bureau of Communicable Diseases on any potential response needed in Wisconsin. As a CDC-designated Laboratory Response Network (LRN)	Ongoing

		testing lab, the WSLH has the capacity to presumptively identify monkeypox by PCR testing. At this time (June 8, 2022), any presumptive positive specimens would be sent to CDC for confirmatory testing. Guidance is changing rapidly as this outbreak expands. The WSLH is following these guidance changes closely and has the capacity to scale up testing if needed.	
		RECENT EVENTS and FINDINGS	
March 2022	Notulae Algarum Article	WSLH Environmental Toxicologist Nina Desianti and Wisconsin DNR's Gina LaLiberte co-authored an article revising the taxonomic classification of a diatom species found in Wisconsin wetlands:  Analysis of the type slide of Stauroneis singula J.R.Carter & Denny (Stauroneidaceae, Bacillariophyta) and a comparison with similar taxa  Notulae Algarum, No. 232  http://www.notulaealgarum.org/2022/documents/Notulae%20Algarum%20No.%20232.pdf	Complete
March 8, 2022	CAP re-accreditation	The WSLH's clinical units passed their bi-annual College of American Pathologists inspection and were re-accredited by CAP.	Complete
March 10, and April 15, 2022	Drug Recognition Expert (DRE) Recertification, Wausau and Franklin, WI	Forensic Scientist Kimberle Glowacki provided a lab update at the DRE mandatory trainings	Complete
March 12, 2022	J Neonatal Perinatal Med article	WSLH Newborn Screening Director Dr. Mei Baker co-authored the article -	Complete

		Lack of association between gestational age adjusted TSH percentiles and neurodevelopmental outcomes among preterm infants  J Neonatal Perinatal Med. 2022 Mar 12. doi: 10.3233/NPM-210910	
March 13, 2022	Lifesavers Annual Conference, Chicago, IL	Forensic Toxicology Director Amy Miles gave a presentation on drug trends in the Midwest and moderated a separate session on data harmonization between toxicology and other partners.	Complete
March 18, 2022	State Council on Alcohol and Other Drugs of Abuse	Forensic Toxicology Director Amy Miles provided a presentation on THC isomers and kratom to the Council.	Complete
March 21, 2022	APHL Outreach Model Practices publication	WI Clinical Laboratory Network (WCLN) Coordinator Erin Bowles contributed to the Association of Public Health Laboratories publication "Public Health Laboratory Outreach Model Practices for Infectious Disease Programs".	Complete
		The publication is a compilation of information gathered from nine interviews with public health laboratories that have sustained an outreach program focused on infectious diseases and incorporates strategies to address the challenges surrounding resource limitations.	
		https://www.aphl.org/aboutAPHL/publications/Documents/QSA-2022-ID-Outreach-Model-Practices.pdf	
March 31, 2022	BMC Infectious Diseases journal article	WSLH Communicable Disease Division Director Dr. Allen Bateman and Associate Director Dr. Alana Sterkel and Serology Team Lead TJ Whyte, along with WI DHS and UW-Madison colleagues were co-authors on the article –	Complete

		A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students  BMC Infectious Diseases volume 22, Article number: 314 (31 March 2022)  https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07314-5	
April 2022	Midwest SETAC Meeting	WSLH Environmental Toxicologists presented at the Midwest Society of Environmental Toxicology and Chemistry (SETAC) meeting held in Madison, Wisconsin:  • Detecting SARS-CoV-2 in Wisconsin Wastewater: Community Surveillance For Public Health (Rebecca Fahney)  • Diatom Phosphorus Index: An index for nutrient enrichment impact assessment in wadeable streams based on diatom composition (Nina Desianti)  • Using environmental DNA (eDNA) to detect early infestations of New Zealand Mudsnails (Potamopyrgus antipodarum) in Wisconsin (Dagmara Antkiewicz)	Complete
April 2022	Mothers Against Drunk Driving (MADD)	Forensic Toxicology Director Amy Miles has been asked to sit on the MADD Advisory Board.	Ongoing
April 2022	Assoc of Public Health Laboratories (APHL)	Forensic Toxicology Director Amy Miles has been named lead Chair of the Opioids Biosurveillance Task Force (OBTF) and will be choosing a co-chair for the next initiative.	Ongoing
April 2022	Dane County Traffic Safety Commission (TSC)	Forensic Scientist Supervisor Kayla Neuman has been named Co-Chair of the Dane TSC.	Ongoing

April 2022	Newborn Screening Journal Articles	WSLH Newborn Screening Laboratory Director Dr. Mei Baker and WSLH NBS scientists had two peer- reviewed journal articles published in April -	Complete
		Lack of association between gestational age adjusted TSH percentiles and neurodevelopmental outcomes among preterm infants	
		J Neonatal Perinatal Med. 2022 Mar 12. doi: 10.3233/NPM-210910	
		Newborn Screen for X-Linked Adrenoleukodystrophy Using Flow Injection Tandem Mass Spectrometry in Negative Ion Mode	
		Int. J. Neonatal Screen. 12 April 2022, 8(2), 27; <a href="https://doi.org/10.3390/ijns8020027">https://doi.org/10.3390/ijns8020027</a>	
April 1, 2022	National Traffic Law Center (NTLC)	Forensic Toxicology Director Amy Miles was asked to write a portion of NTLC's Drugged Driving for Prosecutors monograph.	Complete
April 8, 2022	WI Vehicular Homicide Conference	Forensic Scientist Supervisor Kayla Neuman co- presented with the WI Crime Lab and provided another standalone presentation to law enforcement and prosecutors.	Complete
April 9, 2022	Applied Geochemistry journal article	An ongoing collaboration between the WSLH Trace Elements Clean Lab (Dr. Sean Scott) and UW Civil and Environmental Engineering Professor Matthew Ginder-Vogel on research related to radionuclides and groundwater geochemistry resulted in a recent publication -	Complete

		Isotopic analysis of radium geochemistry at discrete intervals in the Midwestern Cambrian-Ordovician aquifer system	
		Applied Geochemistry, 9 April 2022, https://doi.org/10.1016/j.apgeochem.2022.1053 00	
April 15, 2022	Wisconsin Courts (Webinar)	Forensic Scientist Supervisor Kayla Neuman presented Blood Alcohol and Drug Testing for Legal Cases to WI Judges.	Complete
April 19, 2022	National Labroots webinar	WSLH Communicable Disease Division Associate Director Dr. Alana Sterkel was an invited speaker for a national webinar on the public health response to the pandemic.	Complete
April 20, 2022	ASCLS Conference	WSLH Communicable Disease Division Associate Director Dr. Alana Sterkel, WCLN Coordinator Erin Bowles, and Microbiologists Mike Rauch and Kristen Gundlach were invited speakers for the Wisconsin chapter of the American Society for Clinical Lab Science (ASCLS) conference.	Complete
April 26, 2022	AR Technical Conference	The WSLH Communicable Disease Division hosted an Antimicrobial Resistance Technical Conference for the Wisconsin Clinical Laboratory Network. Speakers included WI DHS Deputy Secretary Deb Standridge who thanked the Wisconsin laboratorians for their efforts in the COVID response.	Complete
April 27, 2022	National Judicial College (NJC), Indianapolis, IN	Forensic Toxicology Director Amy Miles presented to the Indiana Judges regarding toxicology issues in court. This presentation was part of Miles' faculty position with NJC.	Complete

April 27, 2022	Open Forum Infectious Diseases journal article	WSLH Communicable Disease Division Associate Director and Microbiologist Associate Coleton King were co-authors on the article  The Role of Isavuconazonium Sulfate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility  Open Forum Infectious Diseases, ofac220, 27 April 2022, <a href="https://doi.org/10.1093/ofid/ofac220">https://doi.org/10.1093/ofid/ofac220</a>	Complete
April 29, 2022	MMWR article about Ft. McCoy measles outbreak	WSLH Communicable Disease Division and WI Department of Health Services staff's efforts were highlighted in the article "Public Health Actions to Control Measles Among Afghan Evacuees During Operation Allies Welcome — United States, September—November 2021" published in the CDC's April 29th Morbidity and Mortality Weekly Report.  Because so many people were involved in the response, CDC told WSLH CDD to pick one author from the WSLH. Staff chose Microbiologist III Rich Griesser since he was front and center in the testing part of the response. Rich was who came in late Sunday and early Monday morning so that we knew it was wild-type measles by the 8 AM call on Labor Day.  https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/m m7117a2-H.pdf	Complete
May 2022	Chemical Response Exercise	This exercise, conducted with the CDC, had two phases. In the first phase, WSLH Chemical Emergency Response unit scientists tested 40 urine and 40 serum specimens for the CDC nerve agent panel. The purpose of this phase was to determine the exposure agent. The WSLH was the only lab selected to perform this testing for the Lab Response Network. The second phase consisted of testing 100 urine specimens for Russian VX nerve agent, as quickly as possible. The WSLH completed the specimen receipt,	Complete

		testing and reporting in 7.3 hours. The evaluation report is pending.	
May 3, 2022	National Judicial College (NJC), Reno, NV	Forensic Toxicology Director Amy Miles presented at the NJC facility to judges from across the country on drug trends and toxicology testimony.	Complete
May 5, 2022	Journal of Analytical Atomic Spectrometry article	Dr. Sean Scott and Dr. Martin Shafer with the WSLH Trace Elements Clean lab are co-authors on the article	Complete
		Simultaneous measurement of lithium isotope and lithium/beryllium ratios in FLiBe salts using MC-ICP-MS	
		Journal of Analytical Atomic Spectrometry	
		https://doi.org/10.1039/D2JA00097K	
		The paper details analytical development work they have been doing for nuclear energy industry partners. As one reviewer said, "I think that this manuscript has an outstanding contribution considering its originality, due to the higher accuracy and precision of Li/Be ratios measurements and a more robust method to characterization of synthesized FLiBe salts."	
May 12, 2022	Applied Geochemistry article	A collaboration between WSLH Trace Elements Clean Lab (Dr. Sean Scott) and UW Civil and Environmental Engineering Professor Matthew Ginder-Vogel on groundwater research in the Fond du Lac area where the aquifer system transitions from being regionally confined by the Maquoketa shale in eastern WI to being unconfined towards the west resulted in a published journal article. This shale unit has essentially sealed old groundwater beneath it, and where the Maquoketa shale disappears there are some interesting geochemical changes. Maquoketa shale is not present in most of Wisconsin.  Strontium and radium occurrence at the boundary	Complete
		of a confined aquifer system	

		Amy Plechacek, Sean R. Scott, Madeline B. Gotkowitz, and Matthew Ginder-Vogel  Applied Geochemistry, 12 May 2022.  https://doi.org/10.1016/j.apgeochem.2022.105332	
May 16-20, 2022	Borkenstein Alcohol Course, Bloomington, IN	Forensic Scientists Allen Mello and Traci Reese attended a week-long training course at Indiana University.	Complete
May 25-26, 2022	WPHA-WALHDAB annual conference	WSLH Communications Manager Jan Klawitter and WisCon Consultant Ann Jurkowski staffed an exhibit table showcasing the WisCon program at the annual WI Public Health Association-WI Association of Local Health Departments and Boards annual conference in Wisconsin Dells.  WSLH Scientist Dr. Kayley Janssen also presented a breakout session at the conference on the Wisconsin COVID wastewater surveillance program.	Complete